Access to this content is restrictedLogin with your ESMO Account
The CME test associated with this E-Learning Module has now expired.
- To provide state-of-the art in the treatment of locally-advanced non-small cell lung cancer (NSCLC) with chemo-radiotherapy
- To discuss in depth strategies of association of chemotherapy and radiotherapy, data from clinical trials, outcomes and toxicity profiles
- To provide an update on recent data in the field of locally-advanced NSCLC in terms of radiotherapy techniques and medical treatments illustrated with findings from clinical studies and enabling clinical uptake
This E-learning module provides an excellent overview of the clinical management of patients with locally-advanced non-small cell lung cancer (NSCLC). This group of patients is very heterogeneous according to mediastinal lymph node burden.
The objectives of treatment are the local control of thoracic tumour and lymph nodes extension, as well as micro-metastatic disease control. Despite progress in therapeutic strategies, prognosis remains poor. About 30% of NSCLC are locally-advanced, mainly unresectable.
The author starts the presentation giving the historic background, explaining that radiotherapy became standard of care in these patients half a century ago, with radiotherapy schedule used until now in many countries. However, in recent years, the aim of several studies has been to optimise radiotherapy administration in terms of total dose and using new technologies. Furthermore, a number of randomised phase III trials have shown that chemo-radiotherapy is better in terms of survival than radiotherapy alone.
The author provides further analysis of data on concomitant vs. sequential chemo-radiotherapy, discusses which chemotherapy to associate with radiotherapy, induction vs. consolidation chemotherapy, with illustration from clinical studies findings and results of meta-analysis.
An exhaustive section is dedicated to which radiotherapy to use nowadays, with details on techniques and target definition. A further section is devoted to targeted therapies and chemo-radiotherapy with illustration of studies in patients with oncogenic driver, followed by recent approaches in combining immunotherapy and radiotherapy, outcomes and toxicities.
The author provides very clear clinical practice messages about chemo-radiotherapy being the standard treatment for patients with unresectable stage III NSCLC, but only 40% of patients with unresectable stage III NSCLC are eligible for concurrent chemo-radiotherapy. For the other patients, sequential chemo-radiotherapy, chemotherapy or radiotherapy alone are preferable.
At the end of the module, the author discusses the progress in management considering whether it is due to better treatment or better patient selection. He concludes that the overall survival improvement in the past 10 years, can be due to a better selection of patients, the impact of new radiotherapy techniques and better management of chemo-radiotherapy and treatment-related toxicities.
Declaration of interest
Pierre Fournel has reported:
BMS, ASTRA-ZENECA, TAKEDA: Advisory Board, Personal.
MSD: Invited Speaker, Personal
BMS and IPSEN: Local PI, Institutional
This E-Learning module was published in 2018. The CME test expired in 2020. The author provided a module update as PDF presentation in 2021.